Mantle cell lymphoma stage III – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 12:22:27 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Mantle cell lymphoma stage III – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on CAR-T-cell Therapy with Rituximab and Ibrutinib for Patients with High-Risk Mantle Cell Lymphoma https://clinicaltrials.eu/trial/study-on-car-t-cell-therapy-with-rituximab-and-ibrutinib-for-patients-with-high-risk-mantle-cell-lymphoma/ Wed, 29 Apr 2026 14:26:00 +0000 https://clinicaltrials.eu/trial/study-on-car-t-cell-therapy-with-rituximab-and-ibrutinib-for-patients-with-high-risk-mantle-cell-lymphoma/ This clinical trial is focused on studying a type of cancer called Mantle Cell Lymphoma (MCL), which is a rare form of non-Hodgkin’s lymphoma. The study aims to explore the effectiveness of a treatment strategy using a special type of therapy known as CAR-T-cell treatment with a medication called KTE-X19. This treatment involves using the patient’s own immune cells, which are modified to better fight cancer cells. The trial will compare this approach to the standard treatment methods currently used for patients with high-risk MCL.

Participants in the study will be divided into two groups. One group will receive the experimental treatment, which includes a combination of Rituximab and Ibrutinib followed by the CAR-T-cell therapy. The other group will receive the standard treatment, which is the usual care provided for MCL. The study will also involve the use of several other medications, including Thiotepa, Cisplatin, Etoposide, Melphalan, Cytarabine, Cyclophosphamide, Doxorubicin, Filgrastim, Oxaliplatin, Prednisolone, Bendamustine, Carmustine, Pegfilgrastim, Fludarabine, Vincristine Sulfate, Rituximab, Dexamethasone, and Tocilizumab, which are used to support the treatment process.

The purpose of the study is to compare the effectiveness of the CAR-T-cell treatment strategy with the standard treatment in patients who have not been treated for MCL before. Participants will undergo a series of treatments and follow-ups over a period of time to monitor their response to the therapy. The study will help determine if the new treatment approach can improve outcomes for patients with high-risk MCL compared to the current standard of care.

]]> Study on Ibrutinib and Drug Combination for Patients with Generalized Mantle Cell Lymphoma https://clinicaltrials.eu/trial/study-on-ibrutinib-and-drug-combination-for-patients-with-generalized-mantle-cell-lymphoma/ Wed, 29 Apr 2026 14:22:29 +0000 https://clinicaltrials.eu/trial/study-on-ibrutinib-and-drug-combination-for-patients-with-generalized-mantle-cell-lymphoma/ This clinical trial is focused on studying a type of cancer called mantle cell lymphoma, which is a rare form of non-Hodgkin’s lymphoma. The study is investigating the effectiveness of a treatment that includes a combination of medications: Rituximab, Ibrutinib, and Ara-C (cytarabine). Ibrutinib is a medication that works by blocking certain proteins that help cancer cells grow. The purpose of the study is to determine the best treatment approach for patients with generalized mantle cell lymphoma.

Participants in the study will be randomly assigned to one of three groups. The first group will receive a standard treatment known as R-CHOP followed by R-DHAP and an autologous stem cell transplant (ASCT). The second group will receive R-CHOP with Ibrutinib, followed by R-DHAP, ASCT, and maintenance therapy with Ibrutinib. The third group will receive R-CHOP with Ibrutinib, followed by R-DHAP and maintenance therapy with Ibrutinib, but without the stem cell transplant. The study aims to compare the outcomes of these different treatment strategies.

The trial will monitor participants over a period to assess their response to the treatment, focusing on how long they remain free from disease progression or any other complications. The study will also look at overall survival rates and the occurrence of any side effects. This research is part of a larger effort to improve treatment options for patients with mantle cell lymphoma.

]]>